Zim Laboratories Limited has informed the Exchange about Acquisition
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zim Laboratories' Board has approved an investment of up to AED 4,50,000 (approximately ₹1 crore) in ZIM Scientific Office L.L.C., its step-down subsidiary based in Dubai, UAE. The investment will be made through ZIM Laboratories FZE, the company's wholly owned subsidiary, and ZIM Scientific Office will remain 100% owned. The target entity was incorporated in November 2024 in the pharmaceutical sector and currently has zero turnover. The purpose is to expand and develop the company's pharmaceutical business in the GCC (Gulf Cooperation Council) region. The transaction is classified as a related party transaction (promoter Zulfiquar Kamal is on the target's board) but is being done at arm's length pricing. Completion is expected within 2-3 months of fund transfer.
This is a relatively small capital infusion into a newly formed, wholly owned step-down subsidiary rather than a major acquisition. The move signals the company's intent to grow its pharmaceutical presence in the Middle East, but the small size means limited immediate impact on financials or stock price.